Index

abdomen examination, 5
abdominal complications, 294
acalculous cholecystitis, 297
diverticulitis, 297
gastrointestinal haemorrhage, 295–96
mesenteric ischaemia, 296
pancreatitis, 296–97
perforations, 294
pseudo-obstruction, 297
risk factors, 294
acalculous cholecystitis, 297
access site complications, 26
ACE inhibitors, 267, 377
active cycle of breathing technique (ACBT), 168
acute aortic syndrome, 45, 347–48
acute coronary syndrome, imaging studies, 45–47
acute lower limb ischaemia, 5
acute hypercapnic respiratory failure, ECMO, 205–6
acute kidney injury (AKI), 119, 120, 149, 154
CABG patients, 314–15
complications, 151
ECMO patients, 199
heart transplant patients, 336
nutritional implications, 162
paediatric surgery complications, 425
pathogenesis, 120
pulmonary endarterectomy patients, 329
acute lower limb ischaemia, 5
acute rejection, lung transplant patients, 344
acute respiratory distress syndrome (ARDS), 250, 365
cell therapies, 369
criteria, 251
definition, 365
ECMO, 203–5, 368
less severe ARDS, 205
severe ARDS, 203–5
following thoracic surgery, 359–60
genero supportive measures, 369
imaging studies, 54
incidence, 365
laboratory investigations, 368
outcomes, 365
pathobiology, 365–67
alveolar epithelial injury, 365–66
circulating cell role, 367
endothelial activation and injury, 366–67
injured lung repair, 367
ventilator associated lung injury, 367
pharmacotherapy, 369
prone positioning, 370
ventilator management, 368
PEEP, 368
protective ventilation, 368
recruitment manoeuvres, 368
ventilatory modes, 368
acute respiratory failure (ARF), 247
hypercarbic, 249–50
decreased tidal ventilation, 250
increased CO₂ production, 249
increased dead space, 250
hypoxaemic, 247–49
diffusion abnormalities, 249
inadequate alveolar oxygen, 247–48
increased venous admixture, 249
shunt, 249
ventilation and perfusion mismatch, 248–49
treatment, 253–54
ECMO, 254
inhaled vasodilators, 253
intubation and mechanical ventilation, 253
non-invasive positive pressure ventilation (NIPPV), 253
prone positioning, 253
restrictive fluid strategy, 254
supplemental oxygen, 253
adrenosine, 353
admission to critical care, xix, xxi
alternative resources, xx
diagnostic and surgical-related factors, xix
fast-track approach, xx
patient related factors, xix
timing, xx
adrenaline, see epinephrine
Advanced Directive (AD), 457
advanced life support (ALS), 211–13
drugs, 213
modifications, 213
non-VT/VF arrests, 213
pulseless VF/VT, 212
age, as risk factor, xxiv
air leak, 360
airway, 213–14
assessment, 59, 231
airway emergencies, 231
failed airway, 232–35
can’t intubate, can’t ventilate (CICV), 233–35
obstruction, 231–32
advanced airway management, 232
assessment, 231
causes, 231
initial management, 232
postextubation, 238
post-extubation emergencies, 237–38
organisation, 238–39
equipment, 238
planning and preparation, 239
staff and training, 238
postextubation emergencies, 237–38
airway obstruction, 238
airway obstruction, 238
unplanned extubation, 237–38
tracheostomy emergencies, 235–37
airway bleeding, 237
blocked tube, 237
dislodgement, 237
airway pressure release ventilation (APRV), 145, 368
albumin, 117–19
alpha, receptors, 123
alpha-adrenoceptor agonists, 134
alveolar epithelial injury, 365–66
Alzheimer dementia, 385
amiodarone, 213
amniotic fluid embolism, 413
analgesia, 135
delirium prevention, 396
infusion pharmacokinetics, 130
lung transplant patients, 344
monitoring, 135
non-opioid analgesia, 137–39
© in this web service Cambridge University Press
www.cambridge.org
Index

analgesia (cont.)
opioids, 136–37
planning, 135–36
regional analgesia, 139–40
thoracic surgery, 357–59
angiography, see coronary angiography
angiotensin receptor blockers (ARBs), 377
antibiotics
administration in the critically ill, 95–97
appropriate antibiotic therapy, 95
catheter related bloodstream infections, 100–1
thrombocytopenia and fibrinogen concentrate, 110
analgesia (cont.)
opioids, 136–37
planning, 135–36
regional analgesia, 139–40
thoracic surgery, 357–59
angiography, see coronary angiography
angiotensin receptor blockers (ARBs), 377
antibiotics
administration in the critically ill, 95–97
appropriate antibiotic therapy, 95
catheter related bloodstream infections, 100–1
thrombocytopenia and fibrinogen concentrate, 110
analgesia (cont.)
opioids, 136–37
planning, 135–36
regional analgesia, 139–40
thoracic surgery, 357–59
angiography, see coronary angiography
angiotensin receptor blockers (ARBs), 377
antibiotics
administration in the critically ill, 95–97
appropriate antibiotic therapy, 95
catheter related bloodstream infections, 100–1
thrombocytopenia and fibrinogen concentrate, 110
fresh frozen plasma, 110
platelets, 108–10, 309
prothrombin complex, 110
recombinant FVIIa, 111
red blood cells, 107–8
blood transfusion. See also blood products algorithms, 308
side effects, 108
transfusion coagulopathy, 309
body composition measurement, 157
Bolam test with the Bolitho amendment, 457
bowel ischaemia, 5, 6
brachial plexus injury, 383
bradycardia, 213
aortic stenosis patients, 318
causes, 77–78
hypothermia response, 226
to pace, 78
brain injury following cardiac arrest, 458–59
brainstem death, 459
BRIsC score, xxv
bronchoalveolar lavage, 30
bronchopleural fistula, 31, 360–61
imaging, 54
bronchopneumonia, 53
bronchospagy, 38
complications, 35
contraindications, 31–32
indications, 28
atelectasis management, 30
haemoptysis diagnosis and management, 30
immunocompromised patients, 30
intubation, 28–29
persistent bronchopleural fistula, 31
respiratory infection diagnosis in ventilated patient, 29–30
thoracic trauma, 30–31
physiological effects, 31
preparation, 32–34
equipment, 32
patient, 32
personnel, 33
precautions, 34
ventilation and oxygenation options, 34
procedure, 35
procedures performed, 31
with conscious sedation, 34
with general anaesthesia, 34–35
bundle branch block, 12
bundle of His, 317
bundles of care, 445
calcineurin inhibitors, 337, 343
side effects, 387
calcium channel blockers, 266, 412
calcium sensitizers, 126–27
Candida infections, 102
can’t intubate, can’t ventilate (CICV), 233–35
oxygen delivery techniques, 233–35
rescue techniques, 233
capnography, 214, 239
carbohydrate, 160
cardiac arrest, 19. See also resuscitation causes, 213
non-VT/VF arrests, 213
out-of-hospital arrest, 220
eyelet percutaneous coronary intervention, 224
family screening, 228
haemodynamics, 224–25
intensive care management, 222
mechanical circulatory support, 226–27
organ donation, 227–28
oxygen therapy, 225
practical approach, 224
prognostic issues, 226
survival, 220
targeted temperature management, 225–26
ventilation, 225
withdrawal of cardiorespiratory support, 226
persistent precipitating pathology, 222
postcardiac arrest brain injury, 458–59
postcardiac arrest myocardial dysfunction, 221
postcardiac arrest syndrome, 220–21
systemic ischaemia/reperfusion response, 222
cardiac death, 459
cardiac ECMO, 193. See also extracorporeal membrane oxygenation (ECMO)
cannulation strategies, 194–96
axillary/subclavian cannulation, 196
carotid artery cannulation, 196
central cannulation, 196
femoral artery cannulation, 194–95
peripheral cannulation, 194
circuit design, 194
complications, 199
contraindications, 194
future directions, 199–200
general patient management, 196–98
indications, 193–94
outcomes, 199
weaning, 434
cardiac injuries, 304
cardiac intensivists in ACTA (CIA), 465–66
cardiac output
low output following paediatric cardiac surgery, 420
mechanical ventilation effects, 147
monitoring, 90–91
cardiac power output (CPO), 374
cardiac tamponade, 17, 244
paediatric, 422, 424
cardiac transplantation. See heart transplantation
cardiomeboliom, 19
cardiogenic shock, 256, 372. See also shock causes, 193
ECMO indications, 193. See also cardiac ECMO
imaging studies, 47–48
neonatal, 419
cardiopulmonary bypass (CPB), 215, 350, 352
neurological complications, 380–81
risk reduction, 381
pregnant patients, 415
cardiorenal syndrome, 372–73
cardiopulmonary disease symptoms, 1
cardiopulmonary imaging, 44
acute aortic syndrome, 45–47
acute coronary syndrome, 45
acute respiratory distress syndrome, 54
aspiration, 53
atelectasis and collapse, 52–53
cardiogenic shock, 47–48
chest pain, 45
chest X-ray, 44
computed tomography, 44–45
pericardial tamponade, 48
pleural effusion, 48
left ventricular failure, 48
surgical complications, 49–50
trauma and surgery associated desaturation, 54
ultrasound, 44
cardiopulmonary bypass. See cardiac bypass
cardioversion, 82
special considerations, 82–83
carotid artery cannulation, 196
catheter insertion, 86. See also arterial catheters; central venous catheters;
pulmonary arterial catheter complications, 86
pregnant patients, 409
catheter related bloodstream infections, 100–1
central line associated bloodstream infections (CLABSI), 100–1, 282
prevention strategies, 282
central venous catheters, 88–89. See also vascular access
central pressures, 89
central venous pressure trace, 89
CentriMag system, 181
cerebrospinal fluid drainage, 352–53
Chelsea Critical Care Physical Assessment tool (CPAx), 167
chest compressions, 211
chest drainage, 357
complications, 74–75
chylethorax, 75
drain malposition, 74
heart injury, 74
infection, 75
intercostal vessel injury, 74
nerve injuries, 74
oesophageal perforation, 75
re-expansion of pulmonary oedema, 74
contraindications, 73
historical background, 70
indications, 70
nursing care, 73
procedure, 70–73
anatomical landmarks, 70
patient positioning, 71
preinsertion preparation, 71
removal of drains, 74
underwater seals, 73
chest electrodes, 7
chest pain, 241
aortic dissection, 243
cardiac tamponade, 244
differential diagnosis, 241
examination, 241
gastrointestinal causes, 245
history, 241
imaging studies, 45
myocardial ischaemia, 242–43
postpercutaneous coronary intervention, 242
postsurgical revascularisation, 242–43
myocardial rupture, 244
myocarditis, 244
pericarditis, 244
superior vena cava syndrome, 243
Takotsubo cardiomyopathy, 245
tension pneumothorax, 244
vascular air embolism, 243–44
wound pain and sternal dehiscence, 245
chest reopening, 215
outside the ICU, 216
chest wall trauma, 302
chest X-ray, 44
pregnant patients, 410
children. See paediatrics
chole cystitis, 245
acalculous, 297
chronic lung allograft dysfunction (CLAD), 344
chronic obstructive pulmonary disease (COPD), xxiv, 252–53
acute exacerbations, 252
extracorporeal carbon dioxide removal (ECCO₂R), 206
lung transplantation, 342–43
management, 252, 253
ventilator complications, 205
chronic thromboembolic pulmonary hypertension (CTEPH), 273, 324
cerebrovascular issues, 329
critical care management, 326–27
drugs, 328
fluid balance, 329
haemato logic, 329
monitoring, 327–28
ventilation, 328
diagnosis, 325
medical management, 325–26
pathophysiology, 324
pulmonary endarterectomy, 326
residual pulmonary hypertension, 329–30
surgical treatment, 324
chylethorax, 75, 425
ciclosporin, 337
circumflex artery, 319
citrate anticoagulation, 153
clinical audit, 466
clinical effectiveness, 446–47
clinical governance, 466
clinical guidelines, 445
clinical information systems (CIS), 449
components of, 449–52
costs and benefits, 452–54
effects on clinical practice, 454–55
clonidine, 134
Clostridium difficile, 39
couagulopathy. See also haemostasis
postoperative tests, 111–14
laboratory tests, 113–14
point-of-care testing, 114
prospective screening, 111
cognitive decline, 385
colloid solutions, 116–17
community acquired pneumonia (CAP), 252
compartment syndrome, 26
computed tomography (CT), 44–45, 389
pregnant patients, 410
genital heart disease, 413–14, 418–22
adult. See grown-up congenital heart disease (GUCH)
incidence, 418
presentations, 418–20
arrhythmias, 420
cardiogenic shock, 419
cyanosis, 418
heart failure and failure to thrive, 420
pulmonary oedema, 420
univentricular circulations, 422
initial palliation, 422
superior cavopulmonary connection, 423
total cavopulmonary connection, 423
consent issues, 456–58
best interests, 457
coronary angiography, 23
deprivation of liberty, 458
medical research, 461
patients who have capacity, 457
patients who lack capacity, 457
constrictive pericarditis, 18
continuous mandatory ventilation (CMV), 144
continuous positive airway pressure (CPAP), 145
continuous renal replacement therapy (CRRT), 151
heart transplant patients, 336
continuous venovenous haemofiltration (CVVH), heart failure patients, 378
contrast complications, 26
contrast induced nephropathy (CIN), 23
coronary angiography, 22
complications, 25–26
access site complications, 26
contrast complications, 26
major adverse cardiac events (MACE), 26
correct, 23
haemostasis and postprocedural care, 24
historical perspective, 22
image acquisition, analysis and interpretation, 24
indications, 22
preprocedural assessment, 24–24
access site preparation, 23
allergy and adverse reaction history, 23
anticoagulation, 24
antiplatelet agents, 24
arterial access route, 22–23
prehydration, 23
premedication, 23
coronary artery bypass grafting (CABG), 313
graft occlusion prevention, 315
haemodynamic management, 313–14
patient population, 313
postoperative complications, 315
acute kidney injury, 314–15
myocardial infarction, 314
postoperative complications, 315
myocardial infarction, 314
postoperative complications, 315
myocardial infarction, 314
chronic hypertension (CTEPH), 273, 324
chronic obstructive pulmonary disease (COPD), xxiv, 252–53
chronic obstructive pulmonary disease (COPD), xxiv, 252–53
acute exacerbations, 252
chronic lung allograft dysfunction (CLAD), 344
chronic obstructive pulmonary disease (COPD), xxiv, 252–53
acute exacerbations, 252

exercise testing, pregnant patients, 409
exponentially weighted moving average (EWMA) charts, 447
extracorporeal carbon dioxide removal (ECCO₂R), 202
COPD, 206
extracorporeal cardiopulmonary resuscitation (eCPR), 193, 218
ethical and legal issues, 460
out-of-hospital arrest management, 226
Extracorporeal Life Support Organisation registry, 199
extracorporeal membrane oxygenation (ECMO), 202, 215
acute respiratory failure, 254
cannulation configurations, 203
cardiac failure management. See cardiac ECMO complications, 5
ethical and legal issues, 460
organ retrieval, 460
future directions, 207
heart transplant patients, 335
indications, 203–7
acute hypercapnic respiratory failure, 205–6
acute respiratory distress syndrome (ARDS), 203–5, 368
lung transplantation, 206
primary graft dysfunction (PGD), 206
pulmonary vascular disease, 206–7
lung transplant patients, 344
microbiological testing, 38
suggested testing set, 39
paediatric, 423–24
platelet transfusion, 109
principles, 202
pulmonary endarterectomy patients, 330
respiratory physiology, 171
therapeutic drug monitoring, 41
extravascular lung water index (EVLWI), 92
extubation, 63–64, 237
controlled, 29
delay, 435
postextubation emergencies, 237–38
airway contamination, 238
airway obstruction, 238
unplanned extubation, 237–38
protocols for early extubation, 434
role of checklists and prompts, 435
screening parameters for early extubation, 434
factor XII deficiency, 403
failed ventilation, 63, 232–35
can’t intubate, can’t ventilate (CICV), 233–35
oxygen delivery techniques, 233–35
rescue techniques, 233
failure to thrive, 420
fat, 160
femoral artery cannulation complications, 194–95
fentanyl, 136
fibrinogen, 110
replacement, 110
fibrinolysis, 309–10
flexible bronchoscopy. See bronchoscopy fluid administration, 116
albumin, 117–19
colloids vs crystalloids, 116–17
colloidal solutions, 119
fluid responsiveness, 121
hydroxyethyl starch (HES), 119
hypertonic solutions, 119
indications, 116
pathophysiology, 116
sepsis patients, 279
fluid balance management, 119–20. See also fluid administration lung surgery patients, 120
pulmonary endarterectomy patients, 329
fluid responsiveness, 19
evaluation, 259
shock patients, 258–59
follow-up, 443–44
Fontan and Fontan-like circulations, 432
forced expiration technique (FET), 168
fresh frozen plasma, 110
Full Outline of UnResponsiveness (FOUR) score, 388
fungus infection, 102. See also infections lung transplant patients, 342
G protein coupled receptors (GPCR), 123
mechanism of action, 123
Gastrointestinal Complications Score (GICS), 294–95
gastrointestinal haemorrhage, 295–96
lower GI bleed, 295–96
upper GI bleed, 295
gender, as risk factor, xxiv
general anaesthesia, bronchoscopy, 34–35
geneetic testing in pregnancy, 415
gestational hypertension, 410
Glanzmann’s thrombasthenia, 403
global end-diastolic volume index (GEDVI), 92
glycerol trinitrate, 412
Gott shunt, 352
grown-up congenital heart disease (GUCH), 427
ICU management, 427–29
cyanotic patient, 428
failing morphological right ventricle, 429
general principles, 427–28
univentricular heart, 429
indications for ICU admission, 429–30
arhythmias, 429
diabetes, 430
haemoptysis, 429
heart failure, 429
intra-aortic balloon pump, 378
intubation, 375
non-invasive ventilation, 375
inherited platelet disorders, 403
haemophilia, 402
transposition of the great arteries, 431
systemic-pulmonary shunt, 431
tetralogy of Fallot, 431
unplanned extubation, 237–38
atrial septal defect, 430
atrioventricular septal defect, 430
grown-up congenital heart disease, 429
haemorrhage.
haemostasis.
haemoptysis
haemophilia, 402
haemofiltration, 149
haemodialysis, 149
haemodiafiltration, 149
grown-up congenital heart disease, 427
von Willebrand’s disease, 402–3
inherited platelet disorders, 403
haemophilia, 402
haemoptysis
bronchoscopy applications, 30
grown-up congenital heart disease patients, 430
haemorrhage. See bleeding
haemostasis. See also coagulopathy
cardiopulmonary bypass effects, 111
diagnostic testing, 111
haemothorax, 301
CABG patients, 315
hand examination, 4
health care support worker, 442
heart block, CABG patients, 315
heart failure, 180, 372
causes, 372
clinical presentation, 372
ECMO application, 193. See also cardiac ECMO
diabetes, 387
endothelialitis, 220
endothelialitis, 220
extracorporeal carbon dioxide removal (ECO₂R), 202
Extracorporeal Life Support Organisation registry, 199
ecchymosis, 430
oxygenation, 375  
treatment goals, 374  
ultrafiltration, 378  
monitoring, 373–74  
venricular assist device  
complications, 187–88  
heart injury in chest drainage, 74  
heart rate, 10  
heart rhythm, 10  
heart transplantation, 180, 333  
complications, 334  
acute cellular rejection, 336  
neurological complications, 385–87  
prevention and risk assessment, 388  
contraindications, 333  
discharge from critical care unit, 337  
patient transfer from operating  
room, 333  
postoperative care, 333–37  
airway and ventilation, 334  
antimicrobial prophylaxis, 337  
cardiovascular, 334–35  
immunosuppression, 336–37  
renal, 336  
preoperative assessment, 333  
HeartWare HVAD, 182  
HELLP syndrome, 411  
heparin, 153, 310, 321. See also  
antiocoagulation  
protonemine effect, 310  
resistance, 403–4  
heparin induced thrombocytopenia  
(HIT), 404–5  
diagnosis, 404  
ICU management, 406  
laboratory testing, 404  
management of patients for  
surgery, 405–6  
antibody positive, 405  
heparin, 405  
treatment, 405  
hepatobiliary complications, 296–97  
acalculus cholecystitis, 297  
pancreatitis, 296–97  
high flow nasal oxygen therapy, 147  
high frequency nasal oxygen (HFNO), 170  
high frequency ventilation (HFV), 146  
high frequency oscillatory ventilation  
(HFOV), 368  
high thoracic epidural analgesia  
(HTEA), 139  
historical perspectives, 462–63  
history, 1  
chest pain, 241  
conscious patient, 1–3  
modification for use in critical care, 1  
pregnant patients, 409  
unconscious patient, 3–4, 224  
Homan's sign, 5  
hydralazine, 376, 412  
hydroxethyl starch (HES), 119  
hypercarbia, 249  
hypercarbic respiratory failure, 249–50  
decreased tidal ventilation, 250  
increased CO₂ production, 249  
increased dead space, 250  
hypertension, 263  
acute, 265  
aetiology, 263–64  
aortic stenosis patients, 318  
classification, 264  
diagnosis, 264–65  
management, 265–67  
medications, 267  
peripertative, 266–67  
postoperative, 267  
preoperative, 265–66  
pulmonary. See pulmonary hypertension  
hypertensive crisis, 270  
hypertensive emergency, 265  
hypertensive urgency, 265  
hypertonic solutions, 119  
hypertrophic cardiomyopathy, 413  
hypoperfusion, 257. See also shock  
signs of, 258  
hypoplastic left heart syndrome  
(HLHs), 422  
hypotension, 257, 279. See also shock  
aortic regurgitation patients, 318  
aortic stenosis patients, 318  
hypothermia, therapeutic, 381. See targeted  
temperature management (TTM)  
hypoventilation, 247–48  
hypovolaemia, 273  
aortic regurgitation patients, 318  
hypovolaemic shock, 256  
hypoxaemic respiratory failure, 247–49  
diffusion abnormalities, 249  
inadequate alveolar oxygen, 247–48  
increased venous admixture, 249  
shunt, 249  
ventilation and perfusion  
mismatch, 248–49  
idiopathic pulmonary fibrosis, 343  
iloprost, 276  
imaging. See cardiothoracic imaging  
immunocompromised patients, 30  
immunosuppression  
lung transplantation, 343  
pharmacological side effects, 387  
Impella device, 175–76, 182  
implemented cardiac devices, 77. See also  
ventricular assist devices (VAD)  
implemented cardioverter defibrillators  
(ICDs), 79  
infection, 281  
antibiotic therapy, 98–100  
magnet mode, 82  
precautions when performing  
procedures, 80–81  
removal, 281  
troubleshooting, 81–82  
incentive spirometry, 168  
indeterminate axis, 12  
direct calorimetry, 158, 160  
induction agents, 337  
infants. See paediatrics  
infections, 38, 278. See also antibiotics;  
microbiological testing; specific infections  
central line associated bloodstream  
infections, 100–1, 282  
chest drainage complications, 75  
fungal infections, 102  
general clinical management,  
279–80  
heart transplant patients, 387  
prophylaxis, 337  
implemented cardiac devices, 98–100,  
281  
lung transplant patients, 341–42  
bacterial, 341–42  
fungal, 342  
viral, 342  
mechanical circulatory support device  
infections, 101–2  
recognition of, 278–79  
screening for resistant organisms, 40  
surgical site, 282–83  
thoracic surgery complications, 361  
ventricular assist devices, 188, 281  
infected endocarditis, 4, 17, 280–81  
antibiotic therapy, 98–100, 280  
diagnosis, 98  
grown-up congenital heart disease  
patients, 430  
patients at high risk, 98  
inferior vena cava diameter, 19  
inflammation  
lung, 367  
resolution, 367  
steroid treatment, 369  
informed consent. See consent issues  
infusion pharmacokinetics, 130  
inotropic agents. See also specific drugs  
heart failure management, 376  
tensive care, 457  
tensive care unit acquired weakness  
(ICAU AW), 385  
termittent positive pressure ventilation  
(IPPV), 169  
termittent renal replacement therapy  
(ERRT), 151  
National Liaison Committee on  
Resuscitation (ILCOR), 220
intra-aortic balloon pump (IABP), 173–75, 335
alternative insertion routes, 174
CABG patients, 313
complications, 174
duration and weaning, 174–75
heart failure management, 378
indications, 174
timing, 173
intracardiac shunts, 19
intracranial haemorrhage, 382
intrathoracic blood volume index (ITBVI), 92
intravascular fluid. See fluid administration
intubating laryngeal mask airway, 63
intubation, 59–64
acute respiratory failure, 253
airway assessment, 59
bronchoscopy and, 34
bronchoscopy applications, 28–29
changing endotracheal tubes, 29
controlled extubation, 29
difficult, 28–29, 62–63
predictors, 59
double lumen tube placement, 29
extubation, 63–64
failed ventilation, 63
heart failure patients, 375
indications, 59
management of the intubated patient, 63
preparation, 59–61
drugs, 60
equipment, 60
patient, 60
sequence of events, 61–62
confirmation of correct position, 62
cricoid pressure, 61
laryngoscopy, 61
preoxygenation, 61
team, 61
trauma patients, 301
invasive monitoring, 185
inverted ratio ventilation (IRV), 145
isoproterenol, 125
J point, 9
jugular venous waveform, 4
junctional ectopic tachycardia (JET), 424
justice, 456
ketamine, 139
Kussmaul’s sign, 5
labelol, 412
labour management, 414
lacerations, lung, 54
lactate levels, 257
Lance–Adams syndrome (LAS), 290
laryngeal view, 62
laryngoscopy, 61
laryngospasm, 238
left anterior descending artery (LAD), 24
left anterior hemiblock (LAHB), 12
left axis deviation, 12
left bundle branch block (LBBB), 12
left circumflex artery (LCx), 24
left main coronary artery (LMCA), 24
left posterior hemiblock (LPHB), 12
left ventricle echocardiography, 15–17
left ventricular assist device (LVAD), 180
complications, 187–189
aortic regurgitation, 189
device failure, 189
infections, 188
neurological complications, 188
postoperative bleeding, 187
right heart failure, 187–188
thrombosis, 188
contraindications, 185
first generation, 181
future directions, 189–90
implantation risk factor assessment, 184–185
cardiac factors, 184
echocardiography, 184
indications, 182
outcome, 189
functional status, 189
quality of life, 189
survival, 189
patient selection, 184
perioperative management during implantation, 185–187
ICU and ward care, 186
preoperative planning, 185
VAD team, 186–187
self care, 187
left ventricular diastolic dysfunction (LVDD), 17
left ventricular dysfunction as risk factor, xxiv
mitral valve surgery patients, 320
left ventricular end-diastolic pressure (LVEDP), 20
left ventricular outflow tract (LVOT) obstruction, 17
velocity-time integral (VTI), 20
left ventricular systolic function (LVSF), 15
ejection fraction (EF), 16
fractional shortening (FS), 16
leg examination, 5
levetiracetam, 292
levosimendan, 126, 275
heart failure management, 377
LiDCO system, 92
lidocaine toxicity, 35
limb electrodes, 7
limitation of treatment, 458
lorazepam, 134, 291
lung collapse, imaging studies, 52–53
lung disease as risk factor, xxiv
lung injuries, 303
lung rest strategy, 205
lung torsion, postoperative, 54
lung transplantation, 340
chronic obstructive pulmonary disease, 342–343
cystic fibrosis, 343
drug interactions, 343
ECMO applications, 206, 344
general ICU issues, 340
idiopathic pulmonary fibrosis, 343
indications, 340
infections, 341–342
bacterial, 341–342
fungus, 342
viral, 342
late admissions to ICU, 344
mobilisation, 344–345
primary graft dysfunction, 340–341
pulmonary hypertension, 343
lysine analogues, 309–10
macrocirculation, 256
macronutrients, 160
carbohydrate, 160
fat, 160
protein, 160
magnesium sulphate, 412
toxicity, 412
magnetic resonance imaging (MRI), 389
pregnant patients, 409
major adverse cardiac events (MACE), 26
mandatory minute ventilation (MMV), 145
manual hyperinflation (MHI), 169
manual insufflation exsufflation, 170
target, 224
mean arterial pressure (MAP), 263
phenylephrine effect, 127
motive, 342
mechanical chest compression devices (MCCDs), 226
mechanical circulatory support (MCS), 173, 180.
See also ventricular assist devices (VAD)
contraindications and complications, 183
device infections, 101–2
heart transplant patients, 335
Impella device, 175–76
intra-aortic balloon pump (IABP), 173–75
out-of-hospital arrest management, 225, 226–27
paediatric, 423–24
TandemHeart device, 176
temporary, 180–81
CentriMag system, 181
indications, 180–81
types of, 181
mechanical ventilation, 142. See also mechanical ventilation
acute respiratory failure, 253
cardiac ECMO patients, 198
heart transplant patients, 334
modes, 143, 144–45
airway pressure release ventilation
(APRV), 145
assist-control ventilation (AC), 145
biphasic positive airway pressure
(BIPAP), 145
continuous mandatory ventilation
(CMV), 144
continuous positive airway pressure
(CPAP), 145
interruption positive pressure
ventilation (IPPV), 169
mandatory minute ventilation
(MMV), 145
pressure support ventilation (PSV), 145
selection of, 144
synchronised intermittent mandatory
ventilation (SIMV), 145
physiology, 147–48
cardiovascular effects, 147
respiratory effects, 147–48
principles, 143–44
pressure control ventilation, 144
pressure regulated volume controlled
ventilation (PRVC), 143
volume control ventilation, 143
prolonged. See weaning from mechanical ventilation
protective ventilation, 147
pulmonary endarterectomy patients, 328
special modalities, 145–47
differential ventilation, 146–47
high frequency ventilation (HFV), 146
inversed ratio ventilation (IRV), 145
neurally adjusted ventilatory assist
(NAV A), 146
respiratory aspects, 147
non-invasive ventilation (NIV), 147
technical aspects, 142
cycling phase, 142
limiting phase, 142
triggering phase, 142
variables, 143
expiration, 143
inspiration, 143
ventilator hyperinflation (VHI), 170
weaning from. See weaning from mechanical ventilation
medical emergency teams (MET), 216
medical negligence, 460
Mental Capacity Act, 2005, 457
mesenchymal stem cells (MSCs), 369
mesenteric ischaemia, 296
metabolisable energy, 157, 158
methylen blue, 128
methylprednisolone, 336
microarray technology, 42
microbiological testing, 38
antibiotic susceptibility testing, 41
liaison with infection specialists, 42
microscopy and culture, 40–41
new technologies, 41
mass spectometry, 42
molecular testing, 41
sequencing, 42
ordering tests, 38
results interpretation, 42
sampling approaches, 38–40
screening for resistant organisms, 40
surgical samples, 40
therapeutic drug monitoring, 41
microcirculation, 256
midazolam, 133
milrinone, 125–26, 377
mitral regurgitation, 318, 319
combined valvular pathologies, 321
mitral stenosis, 318, 319, 320
mitral valve, 319
calcification, 319
repair, 321
systolic anterior motion (SAM), 321
mitral valve surgery, 318–20
anatomical considerations, 318–19
common ICU problems, 320
atrial fibrillation, 320
left ventricular dysfunction, 320
right ventricular dysfunction, 320
ventilatory failure, 320
psysiological considerations, 319–20
mobilisation, 167–68
lung transplant patients, 344–45
modelling. See risk models
molecular testing, 41
morphine, 136
MRSA screening, 40
mTOR inhibitors, 337
multidisciplinary teams, 445–46
multidrug resistant organisms (MDR), 103
Multipe platelet function assay, 114
Mustard/Senning procedure, 431
mycopenolate mofetil (MMF), 336
myocardial infarction
CABG patients, 314
chest pain, 242–43
post percutaneous coronary intervention, 242
postsurgical revascularisation, 242–43
following thoracic surgery, 363
imaging studies, 45
myocardial rupture, 244
myocarditis, 244
myoclonic status epilepticus (MSE), 290
myoglobin, 290
nasogastric feeds. See enteral nutrition
neck examination, 4–5
negligence, 460
neonates. See also congenital heart disease;
 paediatrics
arhythmias, 420
cardiogenic shock, 419
cyanosis, 418
management, 419
pulmonary oedema, 420
nerve injuries in chest drainage, 74
nitrates, heart failure management, 376
neuromuscular blockade, 140
neurally adjusted ventilatory assist
(NAVA), 146
neurological complications, 380
brachial plexus injury, 383
cardiopulmonary bypass, 380–81
risk reduction, 381
cognitive decline, 385
considerations with cardiac surgery, 380
encephalopathy, 382
neurally adjusted ventilatory assist
(NAVA), 146
clinical assessment, 388
neuroimaging, 389
neurophysiologic investigations, 389
optic neuropathies, 383
peripheral nervous system, 383–85
prevention, 388
stroke, 381–82
transplantation related
complications, 385–87
neuromuscular blockade, 140
nitrates, heart failure management, 376
nitric oxide, 276, 422
non-convulsive seizures (NCS), 285, 290
nitric oxide, 276, 422
non-convulsive status epilepticus (NCSE), 285, 290, 383
non-invasive ventilation (NIV), 147, 170
See also ventilation
acute respiratory failure, 253
heart failure management, 375
role in difficult weaning from mechanical ventilation, 435–36
weaning failure, 438–39
non-malfeasance, 456
norepinephrine, 124, 275, 377
nursing team, 441–43
advanced nursing roles, 443
bedside nurse, 441–42
education team, 441
health care support worker, 442
hierarchy, 442
lead nurse, 442
matron, 442
nurse manager, 442
shift leader, 443
Index

nutritional assessment, 157
nutritional requirements, 157–59
energy balance, 157
energy intake, 157
in disease, 159–60
obstructive shock, 256
œdema, 5
oesophageal injury, 305
perforation, 297
in chest drainage, 75
oesophageal rupture, 245
openness, 447
opioids analgesia, 136–37
optic neuropathies, 383
organ donation, 227–28, 459
donation after brain death, 459
donation after circulatory death, 459
ECMO patients, 460
otracheal intubation. See intubation
outcome measures, 166–67
outrage, 443
oxycodone, 136
oxygen therapy, acute respiratory
failure, 253
P wave, 9
pacing
complications, 80
implant complications, 80
implantable cardioverter defibrillators
(ICDs), 79
pacemaker functioning, 78
pacemaker magnet mode, 82
pacemaker types, 79
pacing mode, 78–79
pacing threshold, 78
troubleshooting, 81–82
when to pace, 78
paediatrics
circulation assessment, 418
complications, 424–25
acute kidney injury, 425
arrhythmias, 424
cardiactamponade, 424
chyllothorax, 425
neurological complications, 425
phrenic nerve injury, 425
residual lesions, 424
genital heart disease, 418–22
presentations, 418–20
mechanical circulatory support, 423–24
postoperative care following cardiac
surgery, 420–22
pulmonary circulation and
hypertension, 422
tamponade, 422
univentricular circulations, 422
pain, 135. See also analgesia; chest pain
pancreatitis, 296–97
parenteral nutrition, 161–62
patient preparation
bronchoscopy, 32
chest drainage, 71
intubation, 60
penetrating injuries. See trauma
peptic ulcer, 295
perforated, 298
perfusion, 168
percutaneous coronary intervention (PCI)
recommendations, 224
pericardial tamponade, 4
imaging studies, 48
pericarditis, 424
pericardiography, 17–18
peripartum cardiomyopathy, 408, 413
peritoneal dialysis, 149
phenylephrine, 127–28, 275
phenytoin, 291
phosphodiesterase (PDE) inhibitors, 377
phrenic nerve, 383
injury, 425
physical examination, See examination
physical functional intensive care test
(PFITT), 166
physiotherapy. See rehabilitation; respiratory physiotherapy
PICCO system, 91–92
pimobendan, 126
plasmin, 309
platelets, 108–10, 309
inherited platelet disorders, 403
pleural drainage. See chest drainage
pleural effusion, 70
chylous effusion, 425
imaging studies, 51
ultrasound assessment, 44
pleural space, 70
pneumonia, 252
community acquired, 252
following thoracic surgery, 361
imaging studies, 53
interstitial, 53
lobar, 53
ventilator associated (VAP), 147,
281–82
diagnosis, 29–30
reduction strategies, 281
pneumothorax, 70, 244, 250–51, 360
imaging studies, 51
spontaneous, 250
treatment, 251
positive end expiratory pressure
(PEEP), 144
ARDS patients, 368
postcardiac arrest brain injury, 458–59
postcardiac arrest myocardial
dysfunction, 221
postcardiac arrest syndrome, 220–21
postoperative pulmonary complications
(PPCs), 167. See also respiratory
physiotherapy
post-transplantation lymphoproliferative
disease (PTLD), 387
PR interval, 9
praeclampsia, 5
precordial electrodes, 7
pre-eclampsia, 410
diagnosis, 410
severe pre-eclampsia, 411
pregnancy, 408
amniotic fluid embolism, 413
arrhythmias, 415
cardiopulmonary bypass, 415
cardiovascular changes, 408–9
congenital heart disease, 413–14
coronary artery disease, 414–15
counselling and genetic testing, 415
CVD diagnosis, 409–10
history and examination, 409
deep vein thrombosis, 415
hypertensive disorders, 410–12
postpartum care, 412
hypertrophic cardiomyopathy, 413
labour management, 414
peripartum cardiomyopathy, 413
prehydration, coronary angiography, 23
preoxygenation, 61
premedication, coronary angiography, 23
procalcitonin (PCT), 278
prognosis, xxiii.
primary graft dysfunction (PGD), 206,
281–82
recommendations, 224
treatment, 251
spontaneous, 250
following thoracic surgery, 361
community acquired, 252
ultrasound assessment, 44
chylous effusion, 425
platelets, 108–10, 309
phrenic nerve injury, 425
cardiac tamponade, 424
arrhythmias, 424
acute kidney injury, 425
arrhythmias, 424
chyllothorax, 425
neurological complications, 425
phrenic nerve injury, 425
residual lesions, 424
in disease, 159–60
energy intake, 157
energy expenditure, 158
energy balance, 157
nutritional assessment, 157
nutritional requirements, 157–59
energy balance, 157
energy intake, 157
in disease, 159–60
obstructive shock, 256
œdema, 5
oesophageal injury, 305
perforation, 297
in chest drainage, 75
oesophageal rupture, 245
openness, 447
opioids analgesia, 136–37
optic neuropathies, 383
organ donation, 227–28, 459
donation after brain death, 459
donation after circulatory death, 459
ECMO patients, 460
otracheal intubation. See intubation
outcome measures, 166–67
outrage, 443
oxycodone, 136
oxygen therapy, acute respiratory
failure, 253
P wave, 9
pacing
complications, 80
implant complications, 80
implantable cardioverter defibrillators
(ICDs), 79
pacemaker functioning, 78
pacemaker magnet mode, 82
pacemaker types, 79
pacing mode, 78–79
pacing threshold, 78
troubleshooting, 81–82
when to pace, 78
paediatrics
...
Index

evidence base, 91
heart failure monitoring, 374
historical background, 89
indications, 90
insertion, 90
measurements, 90
pulmonary capillary wedge pressure (PCWP), 272
pulmonary contusions, 54
pulmonary embolism, 19
ECMO applications, 206
imaging studies, 48
pulmonary endarterectomy (PEA), 273, 324, 326
complications, 329–30
pulmonary haemorrhage, 330
reperfusion lung injury, 329
right ventricular failure, 329–30
critical care management, 326–27
cerebrovascular issues, 329
drugs, 328
fluid balance, 329
haematology, 329
monitoring, 327–28
ventilation, 328
operative principles, 326
outcomes, 330
patient selection, 326
surgical techniques, 326
pulmonary haemorrhage, 330
pulmonary hypertension, 272–73, 325
See also chronic thromboembolic pulmonary hypertension (CTEPH)
aetiology, 273
diagnosis, 325
ECMO support, 206, 207
lung transplantation, 343
medical therapy, 275–76
catecholamines, 275
dobutamine, 275
levosimendan, 275
pulmonary vasodilators, 276
vasopressin, 275
vasopressors, 275
monitoring, 274
paediatric, 422
resuscitation, 274–75
supportive care, 273
treatment of underlying causes, 273
pulmonary oedema, 251–52, 253, 372
See also chest drainage
imaging studies, 47
neonatal, 420
re-expansion, 74
pulmonary thromboendarterectomy (PTE), 207
pulmonary torsion, 54
pulmonary vascular disease, ECMO applications, 206–7
pulse pressure variation, 88
QRS axis estimation, 11
QRS complex, 9
QRS transition, 11
QT interval, 9
radial artery, post procedural care, 24
Rastelli procedure, 431
recombinant activated factor VIIa, 111, 311
recruitment manoeuvres, 368
recurrent laryngeal nerve, 384
red blood cells, 107–8
regional analgesia, 139–40
regional wall motion abnormalities (RWMA), 16, 17
rehabilitation
adjuncts and treatment, 165–66
aims, 164–65
barriers, 167
early, 165
outcome measures, 166–67
practicalities and safety issues, 166
remifentanil, 137
renal dysfunction, xxiv
renal replacement therapy (RRT), 149
anticoagulation, 153–54
discontinuation, 154
dose, 152–53
indications, 149, 151–52
monitoring, 154
nutritional implications, 162
outcome, 154
timing, 151
types of, 149–51
reperfusion lung injury, 329
reperfusion response, 222
research and development, 448
ethical and legal issues, 460
consent, 461
publication issues, 461
resonance, 87
respiratory distress, 4
respiratory muscle training, 171
respiratory physiotherapy, 167–70
active cycle of breathing technique (ACBT), 168
breathing exercises, 168
cardiac patients, 171
ECMO patients, 171
incentive spirometry, 168
indications, 167
intermittent positive pressure ventilation (IPPV), 169
manual hyperinflation (MHI), 169
manual insufflation exsufflation, 170
manual techniques, 168
mobilisation, 167–68
positioning, 168
respiratory muscle training, 171
thoracic surgery patients, 171
ventilator hyperinflation (VHI), 170
respiratory quotient (RQ), 159
resting metabolic rate, 158
restrictive cardiomyopathy, 18
restrictive fluid strategy, 254
resuscitation. See also advanced life support (ALS); basic life support (BLS)
cathereter laboratory arrests, 218
general ward, 215–18
guidelines, 211
incidence, 211
late resuscitation, 215
rib fractures, 302
Richmond Agitation-Sedation Scale (RASS), 131, 397
right bundle branch block (RBBB), 12
right ventricular (RV) echocardiography, 17
right ventricular assist device (RVAD), 180, 188
right ventricular dysfunction
grown-up congenital heart disease, 429
heart transplant patients, 335
treatment, 335
right ventricular failure, 17, 188
following thoracic surgery, 363
imaging studies, 48
mitral valve surgery patients, 320
pulmonary endarterectomy patients, 329–30
right ventricular index of myocardial performance (RIMP), 184
risk factors
postoperative, xxv
circulatory, xxv
gastrointestinal/hepatic, xxv
neurological, xxv
renal, xxv
respiratory, xxv
preoperative, xxiv–xxv
age, xxiv
disease extent, xxiv
gender, xxiv
left ventricular function, xxiv
lung disease, xxiv
previous surgery, xxiv
renal disease, xxiv
type of surgery, xxiv
risk management, 447
risk models, xxiii–xxv
postoperative, xxiii, xxv
risk factors, xxv
preoperative, xxiii–xxv
risk factors, xxv–xxv
thoracic surgery, xxv
rocuronium, 60
saline solution, 119
sampling procedures, 38–40
scoring systems, xxiii. See also risk models
sedation, 130–31
alpha-2 adrenoceptor agonists, 134
benzodiazepines, 133–34
bronchoscopy, 34
clonidine, 134
dexametomidine, 135
infusion pharmacokinetics, 130
monitoring, 131
planning, 131–33
propofol, 134
Sedation–Agitation Scale (SAS), 131
seizures, 285
burden of, 285–86
causes and prognostic
significance, 288–90
post cardiac arrest, 290
post cardiac surgery, 288–90
diagnosis, 285
general intensive care
considerations, 290–91
management, 291–92
paediatric, 423
prophylaxis with pre-eclampsia, 412
transplant patients, 387
versus epileptiform activity, 292
selective antegrade cerebral perfusion
(SACP), 351
selective digestive decontamination
(SDD), 281
sepsis, 290. See also infections
definition, 278
general clinical management, 279–80
identification, 278
ventricular assist device
complications, 188
septic shock, 256
sequencing technologies, 42
sequential organ failure score (SOFA), 278
serotonin release assay (SRA), 405
sodium creatinine. See creatinine levels
shivering, hypothermia response, 226
shock
cardiogenic. See cardiogenic shock
definition, 256
diagnosis, 257–58
distributive, 256
epidemiology, 257
hypovolaemic, 256
monitoring, 258–60
ECG, 259–60
fluid responsiveness, 258–59
obstructive, 256
pathophysiology, 256–57
septic, 256
therapeutic strategies, 260–61
shunt
intracardiac, 249
intrapulmonary, 249
sildenafil, 276
single lung ventilation, 146–47
sirolimus, 337
SOFA score, xxv
somatosensory evoked potentials
(SSEPs), 389
spinal cord drainage, 352–53
sputum samples, 40
ST segment, 9
standardised mortality ratio (SMR), 447
status epilepticus, 285
myoclonic (MSE), 290
stem cell therapies, 369
stenal closure, delayed, 422
stenal dehiscence, 245
steroid therapy, 369
stool samples, 39
stroke, 381–82
aortic stenosis patients, 318
risk factors, 388
ventricular assist device
complications, 188
subcuvular cannulation, 196
suctioning, 170, 281
superior cava vena (SVC), 20
superior vena cava syndrome (SVCS), 243
supraventricular arrhythmias, 12–13
surgical samples, 40
surgical site infections, 282–83
management, 283
prevention strategies, 283
Surviving Sepsis Campaigns, 279
suxamethonium, 60
swallowing, with tracheostomy, 66
synchronised intermittent mandatory
ventilation (SIMV), 145
Syntax score, xxv
systemic inflammatory response syndrome
(SIRS), 222
systemic vascular resistance (SVR), 123, 258
systemic-pulmonary shunt, 431
systolic anterior motion (SAM), 321
management, 321
predisposing factors, 321
T wave, 9
tachyarrhythmias, 12–13
tetralogy of Fallot, 431
HeartMate 3, 182
thromboctopenia, 111
thromboelastography (TEG), 114
thromboprophylaxis, 359
thrombosis
dep venous, 5, 415
ventricular assist device
complications, 188
total capillary pulmonary connection, 423
traeobronchial injuries, 303
traeobronchial tears, 54
tracheoinnominate artery fistula, 237
tracheostomy, 64–66, 233
advantages, 64
bronchoscopy and, 34
complications, 237
decannulation, 66
emergencies, 235–37
airway bleeding, 237
blocked tube, 237
dislodgement, 237
targeted temperature management
(TTM), 225–26
physiological responses, 226
tension pneumothorax, 74, 244
tetralogy of Fallot, 431
thoracic aortic aneurysm (TAA), 348–49
endovascular stent graft, 349
medical management, 349
open surgery, 348–49
thoracic endovascular aortic repair
(TEVAR), 353. See also aortic
surgery
thoracic expansion exercises (TEEs), 168
thoracic injury. See trauma
thoracic surgery, 356. See also aortic
surgery
complications, 363
acute respiratory distress syndrome, 359–60
air leak and pneumothorax, 360
atelectasis, 361
bleeding, 363
bronchopleural fistula, 360–61
cardiac dysfunction, 361–63
infections, 361
mortality, 356
reduction of mortality and
complications, 356–59
algesia, 357–59
enhanced recovery, 357
pleural drainage, 357
thromboprophylaxis, 359
video assisted thoracic surgery
(VATS), 356
risk modelling, xxv
thoracotomy, 357
indications, 304
pain control, 344
Thoratec HeartMate 3, 182
thromboctopenia, 111
thromboelastography (TEG), 114
thromboprophylaxis, 359
thrombosis
deep venous, 5, 415
ventricular assist device
complications, 188
indications, 64
insertion technique, 65
percutaneous, 65
surgical, 65
management, 66
percutaneous, 233
swallowing and, 66
timing, 65–66
noses, 64–65
cuffed and uncuffed, 64
fenestrated and non-fenestrated, 65
single and double cannula, 65
weaning protocol, 66
training
current status, 463–64
echocardiography, 465
future of, 465
historical background, 463
opportunities, 464–65
tramedol, 139
tranexamic acid (TXA), 290, 309–10
transducers, 86–87
zeroing, 87
transposition of the great arteries, 431
congenitally corrected, 431
transpulmonary dilation and pulse contour analysis, 91–92
LiDCO system, 92
non-calibrated systems, 92
PiCCO system, 91–92
transpulmonary gradient (TPG), 185
trauma, 301
aortic injury, 304–5
bronchoscopy indications, 30–31
cardiac injuries, 304
cardiothoracic trauma mechanisms, 301
chest wall, 302
clinical assessment, 301
desaturatation, imaging studies, 54
diaphragmatic injury, 305
echocardiography indications, 19
imaging, 301–2
lung injuries, 303
oesophageal injury, 305
thoracic aorta, 349
tracheobronchial injuries, 303
tricuspid annular plane systolic excursion (TAPSE), 184
tricuspid regurgitation, 17, 185, 320
tricuspid valve, 320
surgery, 320–21
troponin, 126
U wave, 9
ultraprotective ventilation, 205
ultrasound imaging, 44
univentricular circulation, 422
grown-up congenital heart disease, 429
initial palliation, 422
superior cavopulmonary connection, 423
total cavopulmonary connection, 423
urine samples, 40
valproate, 292
valve surgery patients, 317
aortic valve, 317–18
common ICU problems, 318
combined valvular pathologies, 321
implant considerations, 321
choice of prosthesis, 321
mitral valve, 318–20
common ICU problems, 320
postoperative anticoagulation, 321
tricuspid valve, 320–21
valvular heart disease, echocardiography, 17
vascular access, 86
arterial catheters, 87–88
cardiac ECMO cannulation strategies, 194–96. See also cardiac ECMO catheter insertion, 86
catheter related bloodstream infections, 100–1
central venous catheters, 88–89
complications, 86
pressure monitoring, 86–87
pulmonary artery catheter, 89–91
vascular air embolism, 243–44
vasoactive receptors, 123
vasodilators, 253, 276, 369
heart failure management, 375
vasopressin, 127, 213, 275
vasopressors, 275
venoarterial carbon dioxide difference (pCO₂, gap), 258
venoarterial ECMO, 202
venovenous ECMO, 202, 203
ventilation, 213–14. See also mechanical ventilation
ARDS patients, 368
protective ventilation, 368
ventilatory modes, 368
decreased tidal ventilation, 230
during bronchoscopy, 34
failed, 63
heart transplant patients, 334
out-of-hospital arrest management, 225
ventilation and perfusion (V/Q) mismatch, 248–49
ventilator associated lung injury (VALI), 147
acute respiratory distress syndrome, 367
burden of, 368
ventilator associated pneumonia (VAP), 147, 281–82
definition, 282
diagnosis, 29–30
reduction strategies, 281
ventilator hyperinflation (VHI), 170
ventricular arrhythmias, 13
ventricular assist devices (VAD), 180
See also mechanical circulatory support (MCS)
complications, 187–89
aortic regurgitation, 189
device failure, 189
infections, 102, 188
neurological complications, 188
postoperative bleeding, 187
right heart failure, 187–88
thrombosis, 188
components, 180
Impella, 175–76
implantable/durable devices, 79
indications, 182
patient selection, 184
types of, 181–82
cardiac factors, 184
patient selection, 184
types of, 181–82
cardiac factors, 184
preoperative planning, 185
types of, 181–82
valve surgery patients, 317
aortic valve, 317–18
common ICU problems, 318
combined valvular pathologies, 321
implant considerations, 321
choice of prosthesis, 321
mitral valve, 318–20
common ICU problems, 320
postoperative anticoagulation, 321
tricuspid valve, 320–21
valvular heart disease, echocardiography, 17
vascular access, 86
arterial catheters, 87–88
cardiac ECMO cannulation strategies, 194–96. See also cardiac ECMO catheter insertion, 86
catheter related bloodstream infections, 100–1
central venous catheters, 88–89
complications, 86
pressure monitoring, 86–87
pulmonary artery catheter, 89–91
vascular air embolism, 243–44
vasoactive receptors, 123
vasodilators, 253, 276, 369
heart failure management, 375
vasopressin, 127, 213, 275
vasopressors, 275
venoarterial carbon dioxide difference (pCO₂, gap), 258
venoarterial ECMO, 202
venovenous ECMO, 202, 203
ventilation, 213–14. See also mechanical ventilation
ARDS patients, 368
protective ventilation, 368
ventilatory modes, 368
decreased tidal ventilation, 230
during bronchoscopy, 34
failed, 63
heart transplant patients, 334
out-of-hospital arrest management, 225
ventilation and perfusion (V/Q) mismatch, 248–49
ventilator associated lung injury (VALI), 147
acute respiratory distress syndrome, 367
burden of, 368
ventilator associated pneumonia (VAP), 147, 281–82
# Index

- weaning from mechanical ventilation (cont.)
  - environment normalisation, 438
  - gas exchange normalisation, 437
  - identification of causes, 437–38
  - impact of prolonged mechanical ventilation, 436
- multidisciplinary team approach, 438
- non-invasive ventilation role, 438–39
- specialised weaning unit role, 436
- trials of unsupported breathing, 438
- weaning to most appropriate level, 439
- Wilson's central terminus, 8
- withdrawing treatment, 458
- withholding treatment, 458
- Wolff–Parkinson–White syndrome (WPW), 13
- wound pain, 245
- wound swabs, 40
- written consent for coronary angiography, 23